David R. Spring

BRIDGE-AD integrates multimodal AD datasets to prioritize disease effectors, identifying 19 functional clusters and validating SCARB2 as a novel candidate.

The paper identifies a covalent binder targeting a lysine in the PIP3 binding site of BTK's PH domain, offering a novel approach to inhibit BTK beyond traditional ATP site targeting.

This study develops D-box peptides that inhibit APC/C by binding Cdc20, showing they are more potent than Apcin and can drive protein degradation.

The paper develops a unified in vitro to in vivo fluorescence lifetime screening platform to identify amyloid β aggregation inhibitors, revealing a new compound effective in multiple models.